MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

MDT

100.5

-1.01%↓

A

136.26

-2.43%↓

VEEV

224.53

-0.43%↓

HQY

84.81

-2.76%↓

NEOG

9.88

-1.4%↓

Search

IQVIA Holdings Inc

Open

SectorHealthcare

236.2 -2.04

Overview

Share price change

24h

Current

Min

236

Max

240.55

Key metrics

By Trading Economics

Income

66M

332M

Sales

83M

4.1B

P/E

Sector Avg

32.693

89.037

Profit margin

8.098

Employees

91,000

EBITDA

102M

883M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+7.96% upside

Dividends

By Dow Jones

Next Earnings

5 lut 2026

Market Stats

By TradingEconomics

Market Cap

3B

40B

Previous open

238.24

Previous close

236.2

News Sentiment

By Acuity

50%

50%

174 / 360 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 sty 2026, 21:55 UTC

Earnings

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 sty 2026, 23:52 UTC

Earnings

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 sty 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 sty 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 sty 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 sty 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 sty 2026, 22:37 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 sty 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 sty 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 sty 2026, 21:44 UTC

Earnings

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 sty 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 sty 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 sty 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 sty 2026, 21:30 UTC

Earnings

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 sty 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Capital One To Acquire Brex >COF

22 sty 2026, 21:13 UTC

Earnings

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 sty 2026, 21:11 UTC

Earnings

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 sty 2026, 21:11 UTC

Earnings

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 sty 2026, 21:10 UTC

Earnings

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 sty 2026, 21:06 UTC

Earnings

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Rev $15.58B >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q EPS $3.26 >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Net Interest Margin 8.26% >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Net $2.13B >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Adj EPS $3.86 >COF

22 sty 2026, 21:05 UTC

Earnings

Capital One 4Q Net Charge-Offs $3.8B >COF

22 sty 2026, 21:05 UTC

Earnings

Intuitive Surgical 4Q EPS $2.21 >ISRG

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

7.96% upside

12 Months Forecast

Average 260.62 USD  7.96%

High 290 USD

Low 230 USD

Based on 15 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

174 / 360 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat